Global Ocular Drug Delivery Technology Market: Trends, Size, Growth, Opportunity and Forecast 2022-2028

 

Treatment of ophthalmic diseases involves the delivery of drugs into the eye. The anterior segment and posterior segment of the eye are the two main categories of ophthalmic diseases, which affect different parts of the eye anatomy. To ensure quick absorption and a quick start to action, ocular medications are directly applied to the affected area or close by. Solutions, suspensions, and emulsions are the most common liquid forms of topical ocular drug formulations for treating diseases in the Ocular Drug Delivery Technology Market segment of the eye. Diseases of the posterior segment are treated with more sophisticated therapies, including implants and injections.

Based on technology, formulation type, disease type, end user, and geography, the global market for ocular drug delivery is divided into submarkets. Topical, iontophoresis, ocular inserts, intraocular implants, in situ gel & punctal plugs, and others are some of the technology-based Ocular Drug Delivery Technology Market segments.

Due to factors like an aging population (which causes macular degeneration and cataracts), excessive eye strain from long work hours, and rising diabetes prevalence (which causes retinopathy), the incidence of ophthalmic diseases and disorders has significantly increased in recent years. Retinopathy is primarily caused by diabetes, which the World Health Organization (WHO) reports affected 422 million people in 2014 and is projected to rise in the near future.

The term Ocular Drug Delivery Technology Market refers to a dosage form, vehicle, or system used to administer or deliver medication to the eye for the treatment of any condition that involves or affects vision. It ranges from straightforward implants for intraocular tissue to simple sterile eye drops for the ocular surface.

Principal Rivals

Alimera Sciences, Valeant Pharmaceuticals International, Clearside Biomedical, Inc., Taiwan Liposome Company, Ltd., Novartis, Pfizer Inc., Envisia Therapeutics, and Graybug Vision Inc. are important market participants in the ocular drug delivery technology market.